even not be amenable to surgery either because of complications or sequelae of surgery. So radiotherapy preferably with chemotherapy remains the mainstay of treatment for LAHNC. [7, 8] The recurrence rates in the surgically treated patients range between 2-10% for the No neck, 8-15% for N1 disease, and 10-30% for N2 disease. In multiple nodes and multiple levels, the neck control is less than 30%. The recurrence rate of 70% or more in this situation is reduced to 20% or less with the postoperative irradiation. [9] In LAHNC (stage III and IV), combined surgery and radiotherapy still give poor survival due to the propensity for local recurrence (upto 50%) and distant metastatic spread (approximately 10-30%). [10] Chemotherapy has been added to standard therapy in recent years in order to improve the curability of these advanced lesions. Most patients with residual or recurrent or metastatic (R/R/M) disease only qualify for palliative treatment. Treatment options in these patients include supportive care only, or in addition single-agent chemotherapy, combination chemotherapy or targeted therapies either alone or in combination with cytotoxicagents. Treatment choice should be based on factors such as performance status (PS), co-morbidity, prior treatment, symptoms, patient preference and logistics. [11] A large number of conventional single agents have been investigated in the past in patients with R/R/M-SCCHN. The four most active and most extensively used agents are taxanes, platinum compounds and 5-fluorouracil (5-FU). These drugs produce a response of short duration, ∼3-5 months, in 15%-30% of cases and only rarely complete response (CR). [12] The taxanes are among the highest scoringagents, with response rates varying between 20% and 43%. Taxanes stabilizes and protect microtubules against disassembly. Cells treated with taxanes have difficulty with the spindle assembly, cell division and also chromosome segregation. Palliative chemotherapy consisting of cetuximab, cisplatin and infusional 5 FU is regarded as the standard of care in head and neck cancers. [13] Head and neck squamous cell carcinoma (HNSCC) is frequently seen in the lower socioeconomic strata of the society in lesser developed countries. Consequently, cetuximabbased combination chemotherapy is received by less than 1% of the eligible patients. TPF regimen, which consists of docetaxel, cisplatin and infusional 5-FU, has become the new standard for induction chemotherapy in the loco-regionally advanced disease setting since the publication of the TAX323/EORTC24971 (Europe) and TAX324 studies (USA). [14] There is a temptation to use this regimen or other three-drug regimens also in the recurrent or metastatic disease setting. Janiniset al observed an overall response rate of 44%, a median time to progression of 7.5months and a median OS of 11 months. [14] About three fourth of the head and neck cancer patients in India, present in stage III or IV where the treatment of choice is concomitant chemoradiation or radiation alone depending on the condition of the patients. Though some percent of patients are cured, most present with residual, recurrent or metastatic disease and need salvage chemotherapy. Platins, 5-fluorouracil, cetuximab, taxanes, methotrexate, gemcitabine, gefitinib, capecitabine, vinorelbine are chemotherapeutically effective drugs in residual, recurrent or metastatic head and neck cancers with response rate varying from 10-44%. Combination chemotherapy is more effective than single agent chemotherapy but is sometimes not tolerated by patients because of poor nutritional status and general condition of the patients Some studies have shown that single agent or double agent chemotherapy may have similar role as triple agent chemotherapy while preserving quality of life. In view of above, a study has been planned to compare triple agent chemotherapy (docetaxel, carboplatin, 5-fu) versus single agent Targeted therapy (gefitinib) in head and neck squamous cell carcinomas, having post radiation, residual, recurrent or metastatic disease.
MATERIAL AND METHODS
A prospective randomized single-center parallel comparative study was conducted at Department of Radiotherapy, Regional Cancer Centre, Pt B D Sharma Post-Graduate Institute of Medical Science, Rohtak. Institutional Board of postgraduate studies approved the protocol for the study. Sixty histopathologically proven patients for squamous cell carcinoma of LAHNC (stage III-IV as per American Joint Committee on Cancer 7th edition, 2010) were enrolled for the study after obtaining informed written consent. The patients were randomly allocated to the study by with/without concomitant chemotherapy) with residual, recurrent or metastatic head and neck squamous cell carcinoma. This group received injdocetaxel 80 mg/m2 iv, inj.carboplatin 300 mg /m2 and inj.5-fu 600 mg/m2 ivinfusion. This regimen was repeated every 3 weeks for 6 cycles (total duration of chemotherapy 15 weeks). The intent of treatment was to deliver minimum 6 cycles of chemotherapy. Group II consists of 30 previously treated patients (as a combination of surgery or radiation therapy with/without concomitant chemotherapy) with residual, recurrent or metastatic head and neck squamous cell carcinoma. This group received oral tablet gefitinib 250mg daily for 3 weeks followed by clinical plus biochemical assessment and commencement of next cycle for 6 cycles (total duration of chemotherapy 15 weeks). From the commencement of treatment, all the patients included in the study were carefully and regularly assessed during treatment at three weekly interval during treatment. Tumor response (both primary and nodal response) was assessed by WHO response criteria. The primary end point will be progression free survival (PFS). The PFS will be calculated in days from the date of randomization to the date of progression. The overall survival was calculated in days from the date of randomization to the date of death or the last date of known contact. In both the groups, the patients were followed up 3 weekly till completion of 6 cycles and thereafter at monthly interval for 6 months. At every visit, each patient was clinically evaluated for local control of disease and treatment related complications. The patients were assessed for any evidence of distant metastasis during each follow up. Statistical analysis was done applying Chisquare test.
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RESULTS
The baseline characteristics of patients including demographic profiles, stages etc. are given in table1.
Patients
Group I, n (%) 
Evaluation of TPF versus Gefitinib in Residual or Recurrent or Metastatic (R/R/M) Head and Neck Carcinoma
Progression Free Survival
Progression free survival (PFS) has been shown in Table 2 
3.3.Overall Survival
Overall survival (OS) has been shown in Table  3 .0. Median overall survival was 168 and 120 days in group I and group II respectively. Graph has been shown in Fig. 3 .0. Results are statistically significant (p<0.001) also mentioned results similar to our study. In this study the overall survival (OS) was higher in TPF based group than oral gefitinib based group.
CONCLUSION
The present study was conducted to determine feasibility, efficacy and tolerability of two schedules i.e. triple agent (docetaxel, carboplatin & 5-fluorouracil) versus oral targeted therapy with gefitinib. Statistics regarding response rate, progression free survival, overall survival, types and frequency of toxicities have been reported. The intended treatment was completed in 46.7% in both the groups. In terms of response rate, patients belonging to TPF group have higher partial response which is 33.3% as compared to 10% in gefitinib arm, and this result is statistically significant (p=0.049), similarly; progression free survival and overall survival was higher in TPF group as compared to oral targeted therapy group with gefitinib.
